Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
211.3 EUR | +1.25% | -15.16% | -11.94% |
Apr. 23 | SARTORIUS STEDIM BIOTECH : Barclays reaffirms its Neutral rating | ZD |
Apr. 22 | Sartorius Stedim: in the red with brokerage comments | CF |
Sales 2024 * | 2.96B 3.16B | Sales 2025 * | 3.37B 3.6B | Capitalization | 20.31B 21.7B |
---|---|---|---|---|---|
Net income 2024 * | 343M 367M | Net income 2025 * | 459M 490M | EV / Sales 2024 * | 7.68 x |
Net Debt 2024 * | 2.27B 2.42B | Net Debt 2025 * | 2.15B 2.3B | EV / Sales 2025 * | 6.71 x |
P/E ratio 2024 * |
57.9
x | P/E ratio 2025 * |
41.7
x | Employees | 10,493 |
Yield 2024 * |
0.36% | Yield 2025 * |
0.53% | Free-Float | 31.97% |
Latest transcript on Sartorius Stedim Biotech
1 day | +1.05% | ||
1 week | -15.16% | ||
Current month | -20.20% | ||
1 month | -22.23% | ||
3 months | -4.70% | ||
6 months | +20.03% | ||
Current year | -11.94% |
Managers | Title | Age | Since |
---|---|---|---|
René Fáber
CEO | Chief Executive Officer | 48 | 19-03-25 |
Chairman | 59 | 07-06-28 | |
Chief Tech/Sci/R&D Officer | 59 | 09-04-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Henri Riey
BRD | Director/Board Member | 62 | 07-06-28 |
Chairman | 59 | 07-06-28 | |
Susan Dexter
BRD | Director/Board Member | 67 | 15-04-06 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.42% | 18 M€ | +4.24% | - | |
0.35% | 5 M€ | +4.56% |
Date | Price | Change | Volume |
---|---|---|---|
24-04-24 | 211.3 | +1.25% | 15 002 |
24-04-23 | 208.7 | +6.21% | 106,382 |
24-04-22 | 196.5 | -2.04% | 113,309 |
24-04-19 | 200.6 | -4.29% | 169,509 |
24-04-18 | 209.6 | -15.69% | 299,152 |
Real-time Euronext Paris, April 24, 2024 at 07:43 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.94% | 21.73B | |
-2.25% | 187B | |
-1.32% | 108B | |
-3.92% | 67.71B | |
+7.99% | 53.07B | |
+15.74% | 47.36B | |
+6.01% | 39.73B | |
+10.81% | 28.56B | |
+2.34% | 26.55B | |
+15.97% | 25.13B |
- Stock Market
- Equities
- DIM Stock